BCRX · XBRL financial data

Biocryst Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BCRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	2	7	6	4	12	19
Research and development	123	209	253	217	175	166
Selling, general and administrative	68	119	159	214	266	349
Operating income (loss)	(175)	(178)	(148)	(104)	(3)	341
Interest expense	15	59	99	108	99	79
Income tax expense (benefit)	0	2	3	0	2	4
Net income (loss)	(183)	(184)	(247)	(227)	(89)	264
Earnings per share, basic USD per share	(1.09)	(1.03)	(1.33)	(1.18)	(0.43)	1.26
Earnings per share, diluted USD per share	(1.09)	(1.03)	(1.33)	(1.18)	(0.43)	1.21
Weighted average shares, basic millions of shares	167	179	186	192	207	210
Weighted average shares, diluted millions of shares	167	179	186	192	207	219

Fiscal years (BCRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	272	504	305	111	105	90
Short-term investments	—	—	—	—	216	185
Marketable securities	28	3	120	278	216	—
Accounts receivable	9	29	51	57	79	107
Inventory	7	16	28	29	31	5
Prepaid and other current assets	6	10	13	20	14	17
Total current assets	324	566	517	496	422	404
Property and equipment, net	7	9	9	8	8	9
Right-of-use asset	—	6	7	9	8	8
Total assets	335	588	550	517	490	514
Accounts payable	19	28	14	21	12	16
Accrued liabilities	34	73	88	103	113	126
Total current liabilities	106	104	106	150	160	196
Long-term debt	120	136	232	303	315	0
Lease liability, non-current	4	6	6	8	8	9
Total liabilities	—	—	—	972	966	633
Accumulated deficit	(1,023)	(1,208)	(1,455)	(1,681)	(1,770)	(1,506)
Total stockholders' equity	(19)	(107)	(295)	(456)	(476)	(119)
Total liabilities and equity	335	588	550	517	490	514
Common shares outstanding (cover page) millions of shares	177	185	188	206	209	251

Fiscal years (BCRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(183)	(184)	(247)	(227)	(89)	264
Stock-based compensation	15	35	45	56	65	85
Depreciation and amortization	1	1	1	2	1	1
Net cash from operating activities	(137)	(142)	(162)	(95)	(52)	347
Net cash from investing activities	(7)	16	(128)	(131)	53	(14)
Proceeds from issuing common stock	93	50	0	0	—	—
Proceeds from long-term debt	—	0	73	300	0	0
Repayments of long-term debt	—	—	—	240	0	300
Net cash from financing activities	303	360	88	32	(6)	(350)
Net change in cash	159	233	(201)	(194)	(6)	(15)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Biocryst Pharmaceuticals	97	180	not reported	257.3M	—	Q3 FY26 10-QSep 30, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.